Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

A hypothesis for the initiation of COPD

E. G. Tzortzaki, N. M. Siafakas
European Respiratory Journal 2009 34: 310-315; DOI: 10.1183/09031936.00067008
E. G. Tzortzaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. M. Siafakas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic obstructive pulmonary disease (COPD) is generally thought to depend on an aberrant immune response to a noxious or infectious agent, which may cause chronic inflammation. However, the initiation of this abnormal response is not fully understood. Here, we propose a new hypothesis for the beginning of COPD, that the immune response to inhaled agents, mainly cigarette smoke, is directed toward the airway epithelium, due to oxidative DNA damage of the lung epithelial barrier cells (LEBCs). The steps of this model are as follows. 1) Cigarette smoke induces oxidative DNA damage of LEBCs. 2) The acquired mutations are expressed at the microsatellite DNA level of LEBCs. 3) The altered LEBCs are recognised by dendritic cells (DCs) as “nonself”. DCs travel, with the new information, to the lymph nodes, presenting it to the naïve T-lymphocytes. 4) A predominant CD8+ cytotoxic T-lymphocyte proliferation occurs. The CD8+ cells, by releasing perforin and granzymes, attack the altered LEBCs activating cell death cascades.

Obviously, the above scenario needs further experimental exploration. However, it is an attractive model for the initiation of the abnormal inflammation in COPD, comprising oxidative DNA damage of LEBCs and host immune response.

  • CD8+ T-lymphocyte
  • dendritic cell
  • lung epithelial barrier cells
  • microsatellite instability
  • oxidative DNA damage
  • perforin

Chronic obstructive pulmonary disease (COPD) is a major health problem worldwide, with increasing prevalence, morbidity and mortality 1–3. Recent guidelines emphasise that COPD is characterised by progressive, not fully reversible airflow limitation, as a result of an abnormal inflammatory reaction of the lungs to inhaled noxious gases and particles 2, 3. The vast majority of COPD patients share chronic cigarette smoke exposure as a common and primary environmental aetiological factor 1–5. Cigarette smoke is a major source of particles, free radicals and reactive chemicals, all of which can produce an overwhelming oxidant burden on the lungs 1–3, 6. The molecular effect of these highly reactive molecules can explain a number of pathologies observed in COPD patients: inflammation, lung destruction and emphysema, airway fibrosis, mucus hypersecretion and skeletal muscle wasting 5. However, only a minority of smokers are diagnosed with clinically relevant COPD 1–4, 7, suggesting that COPD is the result of host–environmental interaction, most probably genetically predetermined 8. Among the candidate genes that have been studied in COPD are those affecting the production of proteases and antiproteases, the ones that modulate the metabolism of toxic substances of smoke, those involved in mucociliary clearance and genes that influence inflammatory mediators 8–10. However, it seems most unlikely that a single molecular pathway will account for the pathogenesis of COPD.

Lately, epigenetic mechanisms such as acquired somatic mutations may represent another fundamental contributor to the molecular pathogenesis of COPD 11. Somatic mutations do not affect the germ line; they are not heritable, although the susceptibility to acquiring such mutations might be controlled by inherited genes 11. During a lifetime, genomic integrity is subject to various types of acquired DNA damage, by exogenous (e.g. ultraviolet light, ionising radiation, toxic chemicals and cigarette smoke) or endogenous agents (e.g. by-products of normal metabolism, such as reactive oxygen species (ROS) and free radicals, stalled replication forks, meiotic recombination and immune system maturation) 12, 13. These critical DNA lesions can result in cell death or a wide variety of genetic alterations, including deletions, translocations, loss of heterozygosity and microsatellite DNA instability 12, 13. In normal conditions, cells are equipped with a number of repair pathways that remove the damage and restore the intact DNA 13. However, increased and persistent oxidative stress may inactivate the human DNA mismatch repair (MMR) system leading to acquired mutations. These mutations permanently alter DNA autorepair ability, resulting in genomic instability 14. Smoking-induced somatic mutations persist for years or decades once they are acquired 15. In agreement with the above hypothesis, somatic genetic alterations have been detected at the microsatellite DNA in COPD patients 16–18.

In the present review, we propose a novel hypothesis for the initiation of COPD, that oxidative stress associated with cigarette smoking might damage DNA of lung epithelial barrier cells (LEBCs), which are further misinterpreted by the host immune system as “nonself”. An atypical adaptive immune response is generated, with the predominance of CD8+ cytotoxic cells, leading to cell death cascades (fig. 1⇓).

Fig. 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1—

The proposed model for the beginning of chronic obstructive pulmonary disease. The oxidative burden of smoking damages the DNA of lung epithelial barrier cells (LEBCs) and inactivates the human DNA mismatch repair system, leading to acquired somatic mutations of LEBCs. Altered LEBCs are recognised as “nonself” by the host, inducing an abnormal immune response towards the altered LEBCs, resulting in the activation of cell death cascades.

HYPOTHESIS

The links between cigarette smoke, oxidative stress, lung inflammation and COPD have been extensively studied, and several theories have been proposed to explain the pathogenesis of COPD 19–26. In this article, we advance a new hypothesis for the initiation of COPD (fig. 1⇑).

In detail, in the beginning of COPD, cigarette smoking affects the air–lung barrier system and, in particular, its cellular component via repeated oxidative stress leading to oxidative DNA damage 27–30. Oxidative stress damages the DNA of LEBCs, leading to acquired somatic mutations 11, 14, 15, and further suppresses key genes of the DNA MMR system, affecting the DNA autorepair ability 11, 14.

Somatic mutations of the LEBCs are an indirect way of activating and polarising the dendritic cell (DC) network, by danger/alarm signals expressed by the altered cells (fig. 2⇓) 31, 32. In the “danger model”, antigen-presenting cells, such as DCs, can be activated by danger/alarm signals produced by self-injured cells, after exposure to pathogens, toxins, mechanical damage and cigarette smoke. This model has been supported by the discovery of endogenous, nonforeign alarm signals 32, including altered mammalian DNA, RNA, heat-shock proteins, interferon (IFN)-a, interleukin-1b, CD40-L and breakdown products of hyaluron 32, 33.

Fig. 2—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2—

Acquired somatic mutations of lung epithelial barrier cells (LEBCs) in chronic obstructive pulmonary disease (COPD). 1) Somatic mutated LEBCs are recognised as nonself by the host. 2) Dendritic cells (DCs) are activated by the “danger/alarm” signals emitted from the altered LEBCs, then 3) DCs travel to the draining lymph nodes to present the new signal. 4) A proliferation of CD8+ cytotoxic T-lymphocytes occurs, then 5) the CD8+ T-cells migrate to the sites of the initial insult and, by releasing perforin and granzymes, attack altered LEBCs, 6) activating cell death. 7) Failed apoptotic cell removal may contribute to COPD pathogenesis by impeding both the resolution of inflammation and the maintenance of alveolar integrity.

Thereafter, the DCs travel to the draining lymph nodes with this endogenous alarm signal, produced by the damaged LEBCs, and they present it to the naïve T-lymphocytes, inducing a proliferation of CD8+ cytotoxic T-lymphocytes 34–36. The CD8+ T-cells migrate to the sites of the initial insult and, by releasing perforin and granzymes, attack the altered LEBCs. Perforin forms pores in the target cells’ membranes, while granzymes, as serine proteases, enter the cytoplasm of the target cells, altering their function and/or activating cell death (fig. 2⇑) 37–39.

STUDIES SUPPORTING THIS HYPOTHESIS

Oxidative DNA damage of LEBCs in COPD

The defence against noxious or infectious agents in the respiratory tract is provided by a number of different mechanisms. In the airways, the LEBCs constitute the first line of defence and have been shown to differ in number and function in smoke-related diseases 40, 41, such as COPD 1–3. Smokers are exposed to thousands of radicals and reactive chemicals with every cigarette, thus oxidative stress is believed to be a central component in COPD pathogenesis 5. ROS, reactive nitrogen species (RNS) and carbon-centred radicals are constituents in both the tar and gas phases of smoke 5. In addition, there are also endogenous sources of ROS, such as those produced by activated alveolar macrophages and neutrophils in response to smoke, which further promote epithelial cell damage 5. Increased ROS production has been directly linked to oxidation of proteins, DNA and lipids, which may cause direct lung injury or induce a variety of cellular responses, through the generation of secondary metabolic reactive species and ROS-mediated molecular mechanisms 12–15, 27. ROS can attack nucleic acids, resulting in base modifications, double base lesions, strand breaks, mismatches and cross-links, leading to increased levels of somatic mutation 11, 14, 27. In the majority of cases, these mutations can be corrected by endogenous repair processes, such as the human DNA MMR system. However, post-translational inactivation of repair enzymes by free radicals may enhance the accumulation of DNA damage 14. Interestingly, female smokers have accelerated metabolism of cigarette smoke leading to increased burden of DNA adducts and mutations, but reduced DNA repair capacity 42, 43 Thus, they are more susceptible to somatic mutations, which may predispose to COPD 42, 43.

Recent studies have reported increased levels of oxidative stress and DNA damage in peripheral blood of patients with COPD 29, 30. Furthermore, microsatellite DNA instability has been reported in sputum cells 16–18 and tissues 15, 44 from COPD patients and smokers, probably reflecting a defective DNA MMR system 14.

Acquired somatic mutations of LEBCs

Molecular damage in the lung epithelium of current and former smokers has been demonstrated, and seems to persist even after smoking cessation 11, 15. Microsatellite DNA instability has been found in sputum cells of COPD patients 16–18, 45. Although sputum is a relatively heterogeneous sample to consider, studies have shown microsatellite instability exclusively in the sputum epithelial cell subpopulation 45, 46, isolated by immunomagnetic separation and further processed for genomic analysis 46.

Microsatellite alterations involve changes in the size of the simple nucleotide repeats of polymorphic microsatellite DNA sequences, resulting in altered electrophoretic mobility of one or both alleles 47. Insertion or deletion of these DNA sequences has been correlated with a high somatic mutational rate and is associated with a defective DNA MMR system 48. The MMR system is a DNA repair mechanism known to be very effective at identifying and subsequently rectifying errors in DNA replication that escape DNA polymerase proofreading during the replication process 49. The MMR corrects base substitutions and frameshift errors, as well as expansions and contractions within microsatellite sequences. In particular, the MMR system is actively involved in the repair of endogenously generated DNA lesions and in the DNA damage signalling response 49. It has been demonstrated that oxidative stress associated with cigarette smoke and chronic inflammation might damage protein components of the MMR system, leading to its functional inactivation 14, 48, 50, 51. Chang et al. 14 reported that noncytotoxic levels of H2O2 inactivate both single-base mismatch and loop repair activities of the MMR system in a dose-dependent fashion, and that this inactivation is most likely due to oxidative damage to hMutSa, hMutSβ and hMutLα protein complexes. Oxidative DNA damage can lead to microsatellite slippage mutations in several model systems 50, 51. In human cell lines, an increase in microsatellite mutations of up to 27-fold after oxidative DNA damage has been reported 51. Moreover, Makris et al. 18 showed a significant association between microsatellite DNA instability and COPD exacerbations, indicating a link between altered DNA MMR system and oxidative DNA damage due to frequent COPD exacerbations or vice versa 18.

Host immune response to the altered LEBCs

Various forms of cell damage lead to DNA fragmentation and destruction of the repair potential that allow its recognition as “foreign” 52, 53. This hypothesis considers that once the LEBCs suffer oxidative DNA damage, they are detected as “nonself” by the primary sensors of the immune system, the DCs 54. DCs, as the main antigen-presenting cells of the lung, populate the whole respiratory tree and can be subdivided into two types: myeloid DCs and plasmacytoid DCs (PDCs) 54.

On the basis of the recognition of self or nonself signals in the presence or absence of danger signals, the interplay of DC antigen uptake and presentation leads to immunosilencing or immunoactivating properties, which designate the outcome of tolerance or defensive immunity within lung 54.

After antigen sampling in the periphery, DCs migrate in a CC chemokine receptor (CCR)7-dependent fashion to regional lymph nodes, where they activate naïve T-cells to proliferate 55. DCs and natural killer (NK) cells appear to regulate one another’s maturation reciprocally 56. The reciprocal interaction of NK cells with PDCs or myeloid DCs profoundly affects innate resistance functions 56. In lung homeostatic conditions, a balance exists between PDCs and myeloid DCs necessary for maintaining tolerance to antigens and avoiding overt inflammation 56. In adaptive immunity, DCs are recruited from the circulation and migrate towards epithelial surfaces, where they capture antigens and recognise “danger signals”. Subsequently, they migrate to regional draining lymph nodes and present sequestered antigens to naïve lymphocytes to induce either a primary immune response or tolerance, dependent on co-stimulatory molecule expression, cytokine release and their state of maturity 57–59.

We consider it highly likely that DCs are implicated in the pathogenesis of COPD, not only in the initiation but also in the perpetuation of its characteristic pattern of chronic airway inflammation 55, 60, 61. Once activated, DCs are encouraged to mature and migrate to draining lymph nodes by chemoattractants, including macrophage inflammatopry protein (MIP)-3β acting on cell surface receptors such as CCR7 55. Depending on the nature of the initial stimulus, DCs will co-operate with naïve lymphocytes to induce one of three predominant responses: T-helper cell (Th) type 1, Th2 or T-regulatory 62.

Induction of a predominantly CD8+ cytotoxic type I T-lymphocyte proliferation

Studies have showed that, in COPD, DCs contribute to the induction of a predominantly CD8+ cytotoxic type I T-lymphocyte response 23, 34, 54, 63. The shift to a predominant type I immune response induces chronic airway inflammation with increased numbers of CD8+ cells and release of IFN inducible protein 10, IFN-γ and tumour necrosis factor (TNF)-α, as well as perforin and granzymes 22, 34, 35. Moreover, B-cells and CD8+ T-cells increase in both the extent of their distribution and in volume, with organisation into lymphoid follicles 22, 24, 64. Similar lymphoid follicles were detected in mice that had developed pulmonary inflammation and progressive alveolar airspace enlargement after smoking 65.

Cross-presentation of self antigens (e.g. injured LEBCs) by DCs to T-cells could lead to the development of auto-immunity 57–59, 66. Moreover, cigarette smoking-induced impairment in DC maturation may enhance CD8+ T-cell proliferation via increased cross-presentation of foreign and/or self antigens 67. In addition, decreased DC maturation may shift the CD4+/CD8+ T-cell ratio in the lungs towards CD8+ cells, as the time required for DCs to launch the proliferative programme for CD8+ is less than that required for CD4+ cells 68. As the proliferative capacity of CD8+ cells is greater than that of CD4+ cells, the latter are more susceptible to the effects of reduced DC maturation 69. CD8+ T-cell differentiation into memory cells is facilitated by CD4+ T-cells. Smoking severity, degree of airway obstruction and emphysema are all related to increased CD8+ cells and/or CD8+/CD4+ ratio 67–69.

In resemblance to host immune response to a viral infection, CD8+ cells attack the altered LEBCs and perform cytotoxic functions, activating cell death cascades 20, 26, 37. In agreement with this, Chrysofakis et al. 37 showed that CD8+ T-cells from patients with COPD produced more perforin and were extremely cytotoxic. Recently, Vernooy et al. 39 investigated protein and mRNA expression of granzyme (Gr)A and B in lung tissue of patients with COPD and found GrA and GrB in CD8+ T-cells, CD57+ NK cells, type II pneumocytes and alveolar macrophages. Both GrA and GrB are involved in perforin-dependent processes leading to DNA fragmentation and initiation of perforin-dependent events that lead to apoptosis 39. Apoptosis, although anti-inflammatory in nature, can lead to persistent inflammation if apoptotic bodies are not removed in time, possibly initiating autoimmune processes 70.

However, we should point out that most resident cells (LEBCs, macrophages, endothelial and extracellular matrix components), when damaged, are capable of inducing an immune response and/or contribute to the oxidative burden 71.

SUMMARY

Cigarette smoke and airway inflammation may cause acquisition of somatic mutations in LEBCs due to oxidative DNA damage. This may primarily affect the DNA MMR system, resulting in failure to preserve genome integrity of LEBCs. Damaged LEBCs are misinterpreted by the host immune system as “nonself”, leading to the clonal expansion of the cytotoxic CD8+ cells, resulting in cell apoptosis and/or necrosis. However, we do acknowledge that a longitudinal study could answer the question of whether increased oxidative inflammatory burden in susceptible smokers is the link between somatic mutations of LEBCs and the host immune system.

Statement of interest

None declared.

  • Received April 30, 2008.
  • Accepted March 5, 2009.
  • © ERS Journals Ltd

References

  1. ↵
    Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398–1420.
    OpenUrlFREE Full Text
  2. ↵
    Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256–1276.
    OpenUrlCrossRefPubMed
  3. ↵
    Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946.
    OpenUrlFREE Full Text
  4. ↵
    Siafakas NM, Tzortzaki EG. Few smokers develop COPD. Why?. Respir Med 2002;96:615–624.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Stevenson CS, Koch LG, Britton SL. Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease – a new take on an old hypothesis. Pharmacol Ther 2006;110:71–82.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:50–60.
    OpenUrlCrossRefPubMed
  7. ↵
    Lundbäck B, Lindberg A, Lindström M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003;97:115–122.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Wang IM, Stepaniants S, Boie Y, et al. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008;177:402–411.
    OpenUrlCrossRefPubMedWeb of Science
  9. Tzortzaki EG, Tsoumakidou M, Makris D, et al. Laboratory markers for COPD in “susceptible” smokers. Clin Chim Acta 2006;364:124–138.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6–14.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Anderson GP, Bozinovski S. Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol Sci 2003;24:71–76.
    OpenUrlCrossRefPubMed
  12. ↵
    Czornak K, Chughtai S, Chrzanowska KH. Mystery of DNA repair: the role of the MRN complex and ATM kinase in DNA damage repair. J Appl Genet 2008;49:383–396.
    OpenUrlPubMedWeb of Science
  13. ↵
    Budzowska M, Kanaar R. Mechanisms of dealing with DNA damage-induced replication problems. Cell Biochem Biophys 2009;53:17–31.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Chang CL, Marra G, Chauhan DP, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 2002;283:C148–C154.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366–1373.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Siafakas NM, Tzortzaki EG, Sourvinos G, et al. Microsatellite DNA instability in COPD. Chest 1999;116:47–51.
    OpenUrlCrossRefPubMedWeb of Science
  17. Zervou MI, Tzortzaki EG, Makris D, et al. Differences in microsatellite DNA level between asthma and chronic obstructive pulmonary disease. Eur Respir J 2006;28:472–478.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Makris D, Tzanakis N, Damianaki A, et al. Microsatellite DNA instability and COPD exacerbations. Eur Respir J 2008;32:612–618.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 2007;4:512–521.
    OpenUrlCrossRefPubMed
  20. ↵
    Siafakas NM. “In the Beginning” of COPD: is evolution important?. Am J Respir Crit Care Med 2007;175:423–424.
    OpenUrlCrossRefPubMedWeb of Science
  21. Baraldo S, Lokar Oliani K, Turato G, et al. The role of lymphocytes in the pathogenesis of asthma and COPD. Curr Med Chem 2007;14:2250–2256.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Barceló B, Pons J, Fuster A, et al. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2006;145:474–479.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Tetley TD. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 2005;4:607–618.
    OpenUrlCrossRefPubMed
  24. ↵
    Agusti A, MacNee W, Donaldson K, et al. Hypothesis: does COPD have an autoimmune component?. Thorax 2003;58:832–834.
    OpenUrlFREE Full Text
  25. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:156–163.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006;129:1673–1682.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J Biochem Mol Biol 2003;36:95–109.
    OpenUrlCrossRefPubMedWeb of Science
  28. Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055–1060.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Ceylan E, Kocyigit A, Gencer M, et al. Increased DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass. Respir Med 2006;100:1270–1276.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Maluf SW, Mergener M, Dalcanale L, et al. DNA damage in peripheral blood of patients with chronic obstructive pulmonary disease (COPD). Mutat Res 2007;626:180–184.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Kool M, Lambrecht BN. Dendritic cells in asthma and COPD: opportunities for drug development. Curr Opin Immunol 2007;19:701–710.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301–305.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Ishii KJ, Suzuki K, Coban C, et al. Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 2001;167:2602–2607.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Barnes PJ, Cosio MG. Characterization of T lymphocytes in chronic obstructive pulmonary disease. PLoS Med 2004;1:e20
    OpenUrlCrossRefPubMed
  35. ↵
    Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711–717.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Tsoumakidou M, Tzanakis N, Kyriakou D, et al. Inflammatory cell profiles and T-lymphocyte subsets in chronic obstructive pulmonary disease and severe persistent asthma. Clin Exp Allergy 2004;34:234–240.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    Chrysofakis G, Tzanakis N, Kyriakoy D, et al. Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest 2004;125:71–76.
    OpenUrlCrossRefPubMedWeb of Science
  38. Zhao MQ, Amir MK, Rice WR, et al. Type II pneumocyte-CD8+ T-cell interactions. Relationship between target cell cytotoxicity and activation. Am J Respir Cell Mol Biol 2001;25:362–369.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Vernooy JHJ, Möller GM, van Suylen RJ, et al. Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:464–472.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Glader P, Möller S, Lilja J, et al. Cigarette smoke extract modulates respiratory defence mechanisms through effects on T-cells and airway epithelial cells. Respir Med 2006;100:818–827.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Rennard SI, Togo S, Holz O. Cigarette smoke inhibits alveolar repair: a mechanism for the development of emphysema. Proc Am Thorac Soc 2006;3:703–708.
    OpenUrlCrossRefPubMed
  42. ↵
    Sin DD, Cohen SB, Day A, et al. Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women. Proc Am Thorac Soc 2007;4:671–674.
    OpenUrlCrossRefPubMed
  43. ↵
    Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764–1772.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Chizhikov VV. Chikina SIu, Tatosian AG, et al. [Development of chronic obstructive pulmonary disease correlates with mini- and microsatellite locus instability]. Genetika 2003;39:694–701.
    OpenUrlPubMed
  45. ↵
    Samara KD, Tzortzaki EG, Zervou MI, et al. Magnetic MicroBeads sputum cell sorting in obstructive airway disease. Eur Respir J 2004;24: Suppl. 48 469s
    OpenUrl
  46. ↵
    Samara K, Tzortzaki E, Neofytou E, et al. Identifying the sputum and BALF cell subpopulation with somatic DNA alterations in COPD. 7th ERS Lung Science Conference. Estoril, Portugal. March, 2009. Abstract PP146
  47. ↵
    Charlesworth B, Sniegowski P, Stephan W. The evolutionary dynamics of repetitive DNA in eukaryotes. Nature 1994;371:215–220.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    Maneval ML, Eckert KA. Effects of oxidative and alkylating damage on microsatellite instability in nontumorigenic human cells. Mutat Res 2004;546:29–38.
    OpenUrlPubMedWeb of Science
  49. ↵
    Harfe BD, Jinks-Robertson S. DNA mismatch repair and genetic instability. Annu Rev Genet 2000;34:359–399.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    Jackson AL, Chen R, Loeb LA. Induction of microsatellite instability by oxidative DNA damage. Proc Natl Acad Sci USA 1998;95:12468–12473.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Zienolddiny S, Ryberg D, Haugen A. Induction of microsatellite mutations by oxidative agents in human lung cancer cell lines. Carcinogenesis 2000;21:1521–1526.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Frenkel K, Karkoszka J, Kim E, et al. Recognition of oxidized DNA bases by sera of patients with inflammatory diseases. Free Radic Biol Med 1993;14:483–494.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    Henson PM, Vandivier RW, Douglas IS. Cell death, remodelling, and repair in chronic obstructive pulmonary disease?. Proc Am Thorac Soc 2006;3:713–717.
    OpenUrlCrossRefPubMed
  54. ↵
    Novak N, Bieber T. Dendritic cells as regulators of immunity and tolerance. J Allergy Clin Immunol 2008;121: Suppl. 2 S370–S374.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am J Respir Crit Care Med 2005;172:530–551.
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005;174:727–734.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Gad M, Claesson MH, Pedersen AE. Dendritic cells in peripheral tolerance and immunity. APMIS 2003;111:766–775.
    OpenUrlCrossRefPubMedWeb of Science
  58. Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005;175:1373–1381.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Tsoumakidou M, Jeffery PK. Dendritic cell maturity and obstructive airway disease. Am J Respir Crit Care Med 2007;176:833
    OpenUrlPubMed
  60. ↵
    D’hulst AI, Vermaelen KY, Brusselle GG, et al. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J 2005;26:204–213.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Bracke KR, D’hulst AI, Maes T, et al. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 2006;177:4350–4359.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    Xu D, Liu H, Komai-Koma M. Direct and indirect role of Toll-like receptors in T cell mediated immunity. Cell Mol Immunol 2004;1:239–246.
    OpenUrlPubMed
  63. ↵
    Demedts IK, Bracke KR, Van Pottelberge G, et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:998–1005.
    OpenUrlCrossRefPubMedWeb of Science
  64. ↵
    Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645–2653.
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    van der Strate BW, Postma DS, Brandsma CA, et al. Cigarette smoke-induced emphysema: a role for the B cell?. Am J Respir Crit Care Med 2006;173:751–758.
    OpenUrlCrossRefPubMedWeb of Science
  66. ↵
    Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004;1:e8
    OpenUrlCrossRefPubMed
  67. ↵
    Robbins CS, Dawe DE, Goncharova SI, et al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am J Respir Cell Mol Biol 2004;30:202–211.
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    van Stipdonk MJ, Hardenberg G, Bijker MS, et al. Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 2003;4:361–365.
    OpenUrlCrossRefPubMedWeb of Science
  69. ↵
    Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003;4:835–842.
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    Bratton DL, Henson PM. Autoimmunity and apoptosis: refusing to go quietly. Nat Med 2005;11:26–27.
    OpenUrlCrossRefPubMedWeb of Science
  71. ↵
    Postma DS, Timens W. Remodeling in asthma and chronic obstuctive pulmonary disease. Proc Am Thorac Soc 2006;3:434–439.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 34 Issue 2 Table of Contents
European Respiratory Journal: 34 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A hypothesis for the initiation of COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A hypothesis for the initiation of COPD
E. G. Tzortzaki, N. M. Siafakas
European Respiratory Journal Aug 2009, 34 (2) 310-315; DOI: 10.1183/09031936.00067008

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A hypothesis for the initiation of COPD
E. G. Tzortzaki, N. M. Siafakas
European Respiratory Journal Aug 2009, 34 (2) 310-315; DOI: 10.1183/09031936.00067008
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • HYPOTHESIS
    • STUDIES SUPPORTING THIS HYPOTHESIS
    • SUMMARY
    • Statement of interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The role of precision medicine in interstitial lung disease
  • GINA Strategy 2021 executive summary and key changes
  • Evaluation of new tests for tuberculosis infection
Show more Perspective

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society